Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 10.00%, near the low end of its 5-year range (0.00%–100.03%).
As of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2025-12-31): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
10.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 855 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Regencell Bioscience Holdings Limited
Market Cap
$3.82B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
10.00%
Market Cap
$4.01B
Gross Margin
76.83%
TTM Avg
-1487.68%
3Y Avg
-5412.33%
5Y Avg
-4507.64%
Market Cap
$4.04B
Gross Margin
61.64%
TTM Avg
80.82%
3Y Avg
86.99%
5Y Avg
87.36%
Market Cap
$3.55B
Gross Margin
71.45%
TTM Avg
69.72%
3Y Avg
68.83%
5Y Avg
69.16%
Market Cap
$3.49B
Gross Margin
-43.89%
TTM Avg
0.67%
3Y Avg
45.02%
5Y Avg
61.14%
Market Cap
$3.49B
Gross Margin
66.09%
TTM Avg
33.05%
3Y Avg
41.52%
5Y Avg
61.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.82B | 0.00% | 0.00% | 0.00% | 10.00% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 37.56% | 35.69% | 33.68% | 34.73% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.01B | 76.83% | -1487.68% | -5412.33% | -4507.64% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.04B | 61.64% | 80.82% | 86.99% | 87.36% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 72.09% | 68.25% | 67.74% | 66.97% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 71.45% | 69.72% | 68.83% | 69.16% |
| LivaNova PLC (LIVN)vs › | $4.14B | 68.18% | 68.59% | 68.31% | 67.52% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | -43.89% | 0.67% | 45.02% | 61.14% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.49B | 66.09% | 33.05% | 41.52% | 61.02% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.50B | 98.25% | 98.17% | 99.09% | 95.85% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-06-30 | 0.00% |
| 2024-12-29 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2022-12-30 | 0.00% |
| 2022-06-30 | 100.03% |
| 2021-12-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2020-12-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-12-30 | 0.00% |
